1. Key Insights

2. Executive Summary of Pulmonary Arterial Hypertension

3. SWOT Analysis for Pulmonary Arterial Hypertension

4. Pulmonary Arterial Hypertension (PAH) Market Overview at a Glance
4.1. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2017
4.2. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2030

5. Disease Background and Overview: Pulmonary Arterial Hypertension (PAH)
5.1. Introduction
5.2. Signs and Symptoms
5.3. Classification of Pulmonary Arterial Hypertension (PAH)
5.3.1. WHO classification
5.3.2. Functional Classification of PAH
5.4. Etiology
5.5. Risk factors
5.6. Pathophysiology
5.7. Diagnosis
5.7.1. Diagnostic Guidelines: European Guidelines of PAH

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Population and Forecast Parameters
6.3. 7MM Total Prevalent Patient Population of Pulmonary Arterial Hypertension [PAH]

7. Country Wise-Epidemiology of Pulmonary Arterial Hypertension (PAH)
7.1. The United States
7.1.1. Total Prevalent Patient Population of PAH in the United States
7.1.2. Sub-type Specific Prevalence of PAH in the United States
7.1.3. Gender specific Prevalence of PAH in the United States
7.2. Germany
7.2.1. Total Prevalent Patient Population of PAH in Germany
7.2.2. Sub-type Specific Prevalence of PAH in Germany
7.2.3. Gender specific Prevalence of PAH in Germany
7.3. France
7.3.1. Total Prevalent Patient Population of PAH in France
7.3.2. Sub-type Specific Prevalence of PAH in France
7.3.3. Gender specific Prevalence of PAH in France
7.4. Italy
7.4.1. Total Prevalent Patient Population of PAH in Italy
7.4.2. Sub-type Specific Prevalence of PAH in Italy
7.4.3. Gender specific Prevalence of PAH in Italy
7.5. Spain
7.5.1. Total Prevalent Patient Population of PAH in Spain
7.5.2. Sub-type Specific Prevalence of PAH in Spain
7.5.3. Gender specific Prevalence of PAH in Spain
7.6. The United Kingdom
7.6.1. Total Prevalent Patient Population of PAH in the UK
7.6.2. Sub-type Specific Prevalence of PAH in the UK
7.6.3. Gender specific Prevalence of PAH in the United Kingdom
7.7. Japan
7.7.1. Total Prevalent Patient Population of PAH in Japan
7.7.2. Sub-type Specific Prevalence of PAH in Japan
7.7.3. Gender specific Prevalence of PAH in Japan

8. Treatment Algorithm
8.1. Current Treatment Practices
8.2. Treatment Guidelines
8.2.1. CHEST Guidelines [The United States]
8.2.2. European Society of Cardiology (ESC) and of the European Respiratory Society (ERS) Guidelines

9. Unmet Needs

10. Case Studies
10.1. A Rare Case of Drug Induced PAH
10.2. A Case Report of Unconventional Delivery of Inhaled NO

11. Organizations related with PAH

12. Marketed Drugs
12.1. Approval and Market Presence

13. Marketed Drugs by Companies
13.1. United Therapeutics Corporation
13.2. Johnson & Johnson
13.3. GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc.
13.4. Bayer AG
13.5. Pfizer

14. Safety and Efficacy of Marketed Drugs

15. Emerging Therapies
15.1. Emerging Drugs Analysis
15.2. Aurora-GT: United Therapeutics
15.2.1. Other Developmental Activities
15.2.2. Clinical Development
15.2.3. Safety and Efficacy
15.3. Ralinepag: United Therapeutics
15.3.1. Other Developmental Activities
15.3.2. Clinical Development
15.3.3. Safety and Efficacy
15.4. Liquidia Technologies
15.4.1. Other Developmental Activities
15.4.2. Clinical Development
15.4.3. Safety and Efficacy
15.5. Bardoxolone Methyl: Reata Pharmaceuticals
15.5.1. Other Developmental Activities
15.5.2. Clinical Development
15.5.3. Safety and Efficacy
15.6. Rodatristat Ethyl: Altavant Sciences
15.6.1. Other Development Activities
15.6.2. Clinical Development
15.6.3. Safety and Efficacy
15.7. Sotatercept: Acceleron Pharma
15.7.1. Other Developmental Activities
15.7.2. Clinical Development
15.7.3. Safety and Efficacy
15.8. PB1064: PhaseBio Pharmaceuticals
15.8.1. Other Developmental Activities
15.8.2. Clinical Development
15.8.3. Safety and Efficacy
15.9. CXA-10: Complexa
15.9.1. Other Developmental Activities
15.9.2. Clinical Development
15.9.3. Safety and Efficacy

16. Other Promising Candidates
16.1. Inhaled Nitric Oxide: Bellerophon Pulse Technologies
16.1.1. Other Developmental Activities
16.1.2. Clinical Development
16.1.3. Safety and Efficacy
16.2. RT234: Respira Therapeutics
16.2.1. Other Developmental Activities
16.2.2. Clinical Development
16.2.3. Safety and Efficacy

17. Pulmonary Arterial Hypertension (PAH): 7 Major Market Analysis
17.1. Key Findings
17.2. Total Market Size of PAH in 7MM
17.3. Market Outlook: 7MM

18. United States
18.1. Total Market size of PAH
18.2. PAH Market Size by Therapies

19. EU5 Countries
19.1. Germany
19.1.1. Total Market size of PAH
19.1.2. PAH Market Size by Therapies
19.2. France
19.2.1. Total Market size of PAH
19.2.2. PAH Market Size by Therapies
19.3. Italy
19.3.1. Total Market size of PAH
19.3.2. PAH Market Size by Therapies
19.4. Spain
19.4.1. Total Market size of PAH
19.4.2. PAH Market Size by Therapies
19.5. United Kingdom
19.5.1. Total Market size of PAH
19.5.2. PAH Market Size by Therapies

20. Japan
20.1. Total Market size of PAH
20.2. PAH Market Size by Therapies

21. Market Drivers

22. Market Barriers

23. Appendix
23.1. Bibliography
23.2. Report Methodology

24. DelveInsight Capabilities

25. Disclaimer

26. About DelveInsight

List of Tables
Table 1: Summary of Pulmonary Arterial Hypertension (PAH) Market, Epidemiology, and Key Events (2017-2030)
Table 2: Pulmonary Arterial Hypertension (PAH)
Table 3: Hemodynamic profiles of pulmonary hypertension
Table 4: Total Prevalent Patient Population of PAH in 7MM (2017-2030)
Table 5: Total Prevalent Population of PAH in the United States (2017-2030)
Table 6: Sub-type Specific Prevalence of PAH in the United States (2017-2030)
Table 7: Gender specific Prevalence of PAH in the United States (2017-2030)
Table 8: Total Prevalent Population of PAH in Germany (2017-2030)
Table 9: Sub-type Specific Prevalence of PAH in Germany (2017-2030)
Table 10: Gender specific Prevalence of PAH in Germany (2017-2030)
Table 11: Total Prevalent Population of PAH in France (2017-2030)
Table 12: Sub-type Specific Prevalence of PAH in France (2017-2030)
Table 13: Gender specific Prevalence of PAH in France (2017-2030)
Table 14: Total Prevalent Population of PAH in Italy (2017-2030)
Table 15: Sub-type Specific Prevalence of PAH in Italy (2017-2030)
Table 16: Gender specific Prevalence of PAH in Italy (2017-2030)
Table 17: Total Prevalent Population of PAH in Spain (2017-2030)
Table 18: Sub-type Specific Prevalence of PAH in Italy (2017-2030)
Table 19: Gender specific Prevalence of PAH in Spain (2017-2030)
Table 20: Total Prevalent Population of PAH in the UK (2017-2030)
Table 21: Sub-type Specific Prevalence of PAH in the UK (2017-2030)
Table 22: Gender specific Prevalence of PAH in the United Kingdom (2017-2030)
Table 23: Total Prevalent Population of PAH in Japan (2017-2030)
Table 24: Sub-type Specific Prevalence of PAH in Japan (2017-2030)
Table 25: Gender specific Prevalence of PAH in Japan (2017-2030)
Table 26: Recommendations for efficacy of drug monotherapy for PAH (group 1) according to WHO functional class.
Table 27: Recommendations for efficacy of initial drug combination therapy for PAH (group 1) according to WHO functional class
Table 28: Recommendations for efficacy of sequential drug combination therapy for PAH (group 1) according to WHO functional class
Table 29: Organizations contributing toward Pulmonary Arterial Hypertension
Table 30: Marketed Drugs for Pulmonary Arterial Hypertension - Approval and Market presence
Table 31: Marketed Drugs developed by United Therapeutics Corporation
Table 32: Marketed Drugs developed by Johnson & Johnson
Table 33: Marketed Drugs developed by GlaxoSmithKline Pharmaceuticals/ Gilead Sciences Inc.
Table 34: Marketed Drugs developed by Bayer (AG)
Table 35: Marketed Drugs developed by Pfizer
Table 36: Safety and Efficacy of Marketed Drugs
Table 37: Aurora-GT, Clinical Trial Description, 2020
Table 38: Ralinepag, Clinical Trial Description, 2020
Table 39: LIQ-861, Clinical Trial Description, 2020
Table 40: Bardoxolone Methyl, Clinical Trial Description, 2020
Table 41: Rodatristat Ethyl, Clinical Trial Description, 2020
Table 42: ACE-011, Clinical Trial Description, 2020
Table 43: PB1064, Clinical Trial Description, 2020
Table 44: PB1064, Clinical Trial Description, 2020
Table 45: iNO, Clinical Trial Description, 2020
Table 46: RT234, Clinical Trial Description, 2020
Table 47: 7 Major Market Size of PAH in USD Million (2017-2030)
Table 48: The US Market size of PAH in USD Million (2017-2030)
Table 49: The US market size of PAH by Therapies in USD Million (2017-2030)
Table 50: Germany Market size of PAH in USD Million (2017-2030)
Table 51: Germany market size of PAH by Therapies in USD Million (2017-2030)
Table 52: France Market size of PAH in USD Million (2017-2030)
Table 53: France market size of PAH by Therapies in USD Million (2017-2030)
Table 54: Italy Market size of PAH in USD Million (2017-2030)
Table 55: Italy market size of PAH by Therapies in USD Million (2017-2030)
Table 56: Spain Market size of PAH in USD Million (2017-2030)
Table 57: Spain market size of PAH by Therapies in USD Million (2017-2030)
Table 58: The UK Market size of PAH in USD Million (2017-2030)
Table 59: The UK market size of PAH by Therapies in USD Million (2017-2030)
Table 60: Japan Market size of PAH in USD Million (2017-2030)
Table 61: Japan market size of PAH by Therapies in USD Million (2017-2030)

List of Figures
Figure 1: SWOT Analysis
Figure 2: Some of the common signs & symptoms of Pulmonary Arterial Hypertension (PAH)
Figure 3: Classification of Pulmonary Arterial Hypertension (PAH)
Figure 4: Functional Classification of PAH
Figure 5: Risk Factors of Pulmonary Arterial Hypertension
Figure 6: Pathophysiology of Pulmonary Arterial Hypertension (PAH)
Figure 7: Pathophysiology of Pulmonary Arterial Hypertension (PAH)
Figure 8: Diagnosis Algorithm of Pulmonary Arterial Hypertension (PAH)
Figure 9: ESC/ERS Guidelines for the diagnosis of pulmonary hypertension
Figure 10: Total Prevalent Patient Population of PAH in 7MM (2017-2030)
Figure 11: Prevalence of PAH in the United States (2017-2030)
Figure 12: Sub-type Specific Prevalence of PAH in the United States (2017-2030)
Figure 13: Gender specific Prevalence of PAH in the United States (2017-2030)
Figure 14: Total Prevalent Population of PAH in Germany (2017-2030)
Figure 15: Sub-type Specific Prevalence of PAH in Germany (2017-2030)
Figure 16: Gender specific Prevalence of PAH in Germany (2017-2030)
Figure 17: Total Prevalent Population of PAH in France (2017-2030)
Figure 18: Sub-type Specific Prevalence of PAH in France (2017-2030)
Figure 19: Gender specific Prevalence of PAH in France (2017-2030)
Figure 20: Total Prevalent Population of PAH in Italy (2017-2030)
Figure 21: Sub-type Specific Prevalence of PAH in Italy (2017-2030)
Figure 22: Gender specific Prevalence of PAH in Italy (2017-2030)
Figure 23: Total Prevalent Population of PAH in Spain (2017-2030)
Figure 24: Sub-type Specific Prevalence of PAH in Spain (2017-2030)
Figure 25: Gender specific Prevalence of PAH in Spain (2017-2030)
Figure 26: Total Prevalent Population of PAH in the UK (2017-2030)
Figure 27: Sub-type Specific Prevalence of PAH in the UK (2017-2030)
Figure 28: Gender specific Prevalence of PAH in the United Kingdom (2017-2030)
Figure 29: Total Prevalent Population of PAH in Japan (2017-2030)
Figure 30: Sub-type Specific Prevalence of PAH in Japan (2017-2030)
Figure 31: Gender specific Prevalence of PAH in Japan (2017-2030)
Figure 32: Treatment Options for Pulmonary Arterial Hypertension (PAH)
Figure 33: Treatment Algorithm of Pulmonary Arterial Hypertension (PAH)
Figure 34: Unmet Needs of PAH
Figure 35: 7 Major Market Size of PAH in USD Million (2017-2030)
Figure 36: Market Size of PAH in the United States, USD Millions (2017-2030)
Figure 37: The U.S. market size of PAH by therapies in USD Million (2017-2030)
Figure 38: Market Size of PAH in Germany, USD Millions (2017-2030)
Figure 39: Germany market size of PAH by therapies in USD Million (2017-2030)
Figure 40: Market Size of PAH in France, USD Millions (2017-2030)
Figure 41: France market size of PAH by therapies in USD Million (2017-2030)
Figure 42: Market Size of PAH in Italy, USD Millions (2017-2030)
Figure 43: Italy market size of PAH by therapies in USD Million (2017-2030)
Figure 44: Market Size of PAH in Spain, USD Millions (2017-2030)
Figure 45: Spain market size of PAH by therapies in USD Million (2017-2030)
Figure 46: Market Size of PAH in the UK, USD Millions (2017-2030)
Figure 47: The UK market size of PAH by therapies in USD Million (2017-2030)
Figure 48: Market Size of PAH in Japan, USD Millions (2017-2030)
Figure 49: Japan market size of PAH by therapies in USD Million (2017-2030)
Figure 50: Market Drivers
Figure 51: Market Barriers

List of Companies
United Therapeutics Corporation
• Johnson & Johnson
• GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc.
• Bayer AG
• Pfizer
• Liquidia Technologies
• Reata Pharmaceuticals
• Altavant Sciences
• Acceleron Pharma
• PhaseBio Pharmaceuticals
• Complexa
• Bellerophon Pulse Technologies
• Respira Therapeutics